Recent advances in targeted degradation in the RAS pathway

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS proteins are frequently mutated in cancer, driving tumor growth via aberrant signaling.
• Targeting RAS has been challenging, but recent inhibitors show promise for specific mutations.
• Limitations of current RAS inhibitors include acquired resistance and combination therapy toxicity.

Purpose of the Study:

• To review advancements in targeted protein degradation (TPD) strategies for RAS pathway modulation.
• To highlight TPD as a novel approach to overcome limitations of traditional RAS inhibitors.
• To discuss the potential of RAS degraders for cancer treatment.

Main Methods:

• Review of recent literature on targeted protein degradation (TPD) strategies.
• Focus on PROTACs and molecular glues targeting RAS pathway components.
• Analysis of TPD approaches for RAS mutations, upstream regulators, and downstream effectors.

Main Results:

• TPD strategies offer a novel mechanism to degrade RAS proteins and related factors.
• Degraders show potential for circumventing acquired resistance to conventional inhibitors.
• TPD enhances therapeutic precision by selectively targeting aberrant signaling.

Conclusions:

• Targeted protein degradation represents a promising therapeutic strategy for cancers driven by RAS mutations.
• RAS degraders may overcome resistance and toxicity issues associated with current therapies.
• Further development of TPD holds significant potential for advancing cancer treatment.